---
figid: PMC9535628__or-48-05-08410-g09
pmcid: PMC9535628
image_filename: or-48-05-08410-g09.jpg
figure_link: /pmc/articles/PMC9535628/figure/f10-or-48-05-08410/
number: Figure 10
figure_title: ''
caption: miR-608 knockdown reverses the effects of circ_0026652 knockdown on multiple
  myeloma chemosensitivity to bortezomib. (A) circ_0026652 expression, (B) miR-608
  expression, (C) relative cell viability under different bortezomib treatment (0,
  1, 2, 4, 8 and 16 nM) and (D and E) cell apoptosis under 4 nM bortezomib treatment
  in U266 cells in the control, si-NC + NC-inhibitor, si-NC + miR-inhibitor, si-circ
  + NC-inhibitor and si-circ + miR-inhibitor groups. (F) circ_0026652 expression,
  (G) miR-608 expression, (H) relative cell viability under different bortezomib treatment
  (0, 0.25, 0.5, 1, 2 and 4 nM) and (I and J) cell apoptosis under 1 nM bortezomib
  treatment in RPMI-8226 cells in the control, si-NC + NC-inhibitor, si-NC + miR-inhibitor,
  si-circ + NC-inhibitor and si-circ + miR-inhibitor groups. *P<0.05, **P<0.01, ***P<0.001.
  miR, microRNA; circ, circular RNA; si, small interfering RNA; NC, negative control.
article_title: Dysregulated circular RNAs are closely linked to multiple myeloma prognosis,
  with circ_0026652 predicting bortezomib-based treatment response and survival via
  the microRNA-608-mediated Wnt/Î²-catenin pathway.
citation: Lu Li, et al. Oncol Rep. 2022 Nov;48(5):195.
year: '2022'

doi: 10.3892/or.2022.8410
journal_title: Oncology Reports
journal_nlm_ta: Oncol Rep
publisher_name: D.A. Spandidos

keywords:
- multiple myeloma
- circular RNA profiles
- circular RNA 0026652
- prognosis
- chemosensitivity to bortezomib

---
